Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia
Laboratory studyOther animalsWith polydatin
This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Rats with testosterone-induced benign prostatic hyperplasia (BPH)
- Dose used in the study
- Co-micronised PEA/polydatin; testosterone propionate 3 mg/kg daily for 14 days induced BPH; PEA/polydatin dose not stated
- Duration
- 14 days
- What was measured
- Prostate weight, dihydrotestosterone, prostaglandin E2, 5alpha-reductase expression, NF-kB pathway activity and apoptosis markers
What the authors reported
Testosterone caused prostate enlargement with raised prostaglandin E2, dihydrotestosterone and 5alpha-reductase expression, plus inflammation and apoptosis pathway changes. The PEA/polydatin composite reduced prostate weight and dihydrotestosterone production in the BPH rats.
Limits of this study
A rat model of testosterone-induced prostate enlargement; it cannot show effect in people. Funding and conflicts not stated in the abstract; the group has used Epitech-linked co-micronised PEA formulations before.
Source
PubMed 28610993 · doi:10.1016/j.taap.2017.06.005
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.